With value investors making inroads into their stock, Edinburgh and Perpetual Income & Growth have started to buy back shares for the first time in over a decade as their boards grapple with underperformance of their former star fund manager.
Biotech Growth has had a dull 12 months after disappointments from its holding in Celgene but with its shares on a 7% discount and fund manager Geoff Hsu anticipating more mergers and acquisitions now could be a good entry point.
JPMorgan Claverhouse, a UK equity income trust run by William Meadon and Callum Abbot, has given Nick Train's Finsbury Growth & Income a run for its money over the past year.
RIT Capital Partners chairman Lord Jacob Rothschild warns investors the global unity that helped propel stock markets over past decade is fracturing.
Activist Edward Bramson brushes off reports his backers are impatient with the lack of detail on his campaign against Barclays bank. Shares in his Sherborne investment company fall 4%.
Investment trust’s holdings in unlisted companies would rise to nearly a fifth of its £7.6 billion of assets, should it continue to back Elon Musk’s electric car maker as a private company.
Investor subscription service plans to launch a new portfolio that applies a momentum-driven process to investment trusts and exchange-traded funds.
Listed fintech fund backed by RIT Capital Partners sees its stake in Zopa lifted by peer-to-peer lender's latest £44 million capital raise.
JPMorgan Japanese becomes first investment trust to issue long-term debt solely in yen, trimming its overall cost of borrowing to a low 1.1% after Bank of Japan held country’s base rate in negative territory.
Star fund manager stops buying Indian stocks after exceeding the 40% country limit for Fundsmith Emerging Equities Trust (FEET).